Bridging the mortality gap: A new challenge in percutaneous coronary intervention for patients with cancer
Although the relationship between cancer and all the secondary events following a percutaneous coronary intervention (PCI) should represent a priority for clinicians and health professionals, the knowledge on this issue is still limited. Possible reasons for this discrepancy are mainly related to the common exclusion of cancer patients from the majority of PCI clinical trials and, consequently, from cardiovascular disease (CVD) national registries.
Source: International Journal of Cardiology - Category: Cardiology Authors: L. Cugusi, C. Cadeddu Dessalvi, M. Deidda, G. Mercuro Tags: Editorial Source Type: research
More News: Angioplasty | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Clinical Trials | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention